Souhaitez-vous accéder aux communiqués récents ?

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential Pharma’s mission to serve the needs of rare disease...

The current indications of soficitinib under development are strategically positioned within the vast dermatology market.

AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences

Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1,...

PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.

ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally.

Kneat will release its financial results for the quarter ended December 31, 2025 on February 25, 2026 and host a conference call on February 26, 2026.

Beghou Names Meredith Ressi President and Chief Growth Officer to optimize for client experience and success.

SHANGHAI, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Headquartered in Shanghai, Arctic Vision (Cayman) Limited (“Arctic Vision”), a global ophthalmic company, announced that it has entered into an agreement...

Beghou's 2026 Biopharma Commercialization Research Report distills key insights, challenges, and operational realities for 2026 and beyond.